The DOI matches its Crossref record; 212 of the 218 references it cites were found in a registry or an index, and 1 are not checked yet.
Xpert ® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance
Open accessAbstract
BACKGROUND: MTB/RIF (Xpert) is a World Health Organization (WHO)-recommended, rapid, automated, nucleic acid amplification assay that is used widely for simultaneous detection of Mycobacterium tuberculosis complex and rifampicin resistance in sputum specimens. This Cochrane Review assessed the accuracy of Xpert in extrapulmonary specimens. OBJECTIVES: To determine the diagnostic accuracy of Xpert a) for extrapulmonary TB by site of disease in people presumed to have extrapulmonary TB; and b) for rifampicin resistance in people presumed to have extrapulmonary TB. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin American Caribbean Health Sciences Literature (LILACS), Scopus, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, the International Standard Randomized Controlled Trial Number (ISRCTN) Registry, and ProQuest up to 7 August 2017 without language restriction. SELECTION CRITERIA: We included diagnostic accuracy studies of Xpert in people presumed to have extrapulmonary TB. We included TB meningitis and pleural, lymph node, bone or joint, genitourinary, peritoneal, pericardial, and disseminated TB. We used culture as the reference standard. For pleural TB, we also included a composite reference standard, which defined a positive result as the presence of granulomatous inflammation or a positive culture result. For rifampicin resistance, we used culture-based drug susceptibility testing or MTBDRplus as the reference standard. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data, assessed risk of bias and applicability using the QUADAS-2 tool. We determined pooled predicted sensitivity and specificity for TB, grouped by type of extrapulmonary specimen, and for rifampicin resistance. For TB detection, we used a bivariate random-effects model. Recognizing that use of culture may lead to misclassification of cases of extrapulmonary TB as 'not TB' owing to the paucibacillary nature of the disease, we adjusted accuracy estimates by applying a latent class meta-analysis model. For rifampicin resistance detection, we performed univariate meta-analyses for sensitivity and specificity separately to include studies in which no rifampicin resistance was detected. We used theoretical populations with an assumed prevalence to provide illustrative numbers of patients with false positive and false negative results. MAIN RESULTS: We included 66 unique studies that evaluated 16,213 specimens for detection of extrapulmonary TB and rifampicin resistance. We identified only one study that evaluated the newest test version, Xpert MTB/RIF Ultra (Ultra), for TB meningitis. Fifty studies (76%) took place in low- or middle-income countries. Risk of bias was low for patient selection, index test, and flow and timing domains and was high or unclear for the reference standard domain (most of these studies decontaminated sterile specimens before culture inoculation). Regarding applicability, in the patient selection domain, we scored high or unclear concern for most studies because either patients were evaluated exclusively as inpatients at tertiary care centres, or we were not sure about the clinical settings.Pooled Xpert sensitivity (defined by culture) varied across different types of specimens (31% in pleural tissue to 97% in bone or joint fluid); Xpert sensitivity was > 80% in urine and bone or joint fluid and tissue. Pooled Xpert specificity (defined by culture) varied less than sensitivity (82% in bone or joint tissue to 99% in pleural fluid and urine). Xpert specificity was ≥ 98% in cerebrospinal fluid, pleural fluid, urine, and peritoneal fluid.Xpert testing in cerebrospinal fluidXpert pooled sensitivity and specificity (95% credible interval (CrI)) against culture were 71.1% (60.9% to 80.4%) and 98.0% (97.0% to 98.8%), respectively (29 studies, 3774 specimens; moderate-certainty evidence).For a population of 1000 people where 100 have TB meningitis on culture, 89 would be Xpert-positive: of these, 18 (20%) would not have TB (false-positives); and 911 would be Xpert-negative: of these, 29 (3%) would have TB (false-negatives).For TB meningitis, ultra sensitivity and specificity against culture (95% confidence interval (CI)) were 90% (55% to 100%) and 90% (83% to 95%), respectively (one study, 129 participants).Xpert testing in pleural fluidXpert pooled sensitivity and specificity (95% CrI) against culture were 50.9% (39.7% to 62.8%) and 99.2% (98.2% to 99.7%), respectively (27 studies, 4006 specimens; low-certainty evidence).For a population of 1000 people where 150 have pleural TB on culture, 83 would be Xpert-positive: of these, seven (8%) would not have TB (false-positives); and 917 would be Xpert-negative: of these, 74 (8%) would have TB (false-negatives).Xpert testing in urineXpert pooled sensitivity and specificity (95% CrI) against culture were 82.7% (69.6% to 91.1%) a
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For lymph node aspirate, we provide evidence using a composite reference because, based on findings from the original review (Kohli 2018), we believe a composite reference standard is preferable for estimating accuracy.”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Kohli 2018
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the previous review (Kohli 2018), we added post hoc a sensitivity analysis limiting inclusion to studies that used one specimen per participant. In this review, we performed a similar sensitivity analysis for Xpert Ultra.”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Kohli 2018
The cited source says what the claim attributes to it.
In the citing paper
“However, for Xpert MTB/RIF in CSF, in comparison with all studies, (sensitivity of 71.1% (60.9 to 80.4), and specificity of 98.0% (97.0 to 98.8)), studies that evaluated only one specimen per participant had lower pooled sensitivity at 63.5% (47.6 to 76.3) and lower pooled specificity at 96.1% (94.2 to 97.4).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Kohli 2018
The cited source says what the claim attributes to it.
In the citing paper
“For Xpert MTB/RIF, in the original review we performed sensitivity analyses by type of extrapulmonary specimen and found that for most analyses, the sensitivity analyses made little difference to any of these findings (Kohli 2018).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Kohli 2018
The cited source says what the claim attributes to it.
In the citing paper
“We previously reported that for CSF, of 2096 tests performed, the pooled proportion of inconclusive Xpert MTB/RIF results was 0.9% (95% CrI 0.3 to 1.9) (Kohli 2018).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Kohli 2018
The cited source says what the claim attributes to it.
In the citing paper
“We previously reported that for lymph node aspirates, in the 1134 tests performed, the pooled proportion of inconclusive Xpert MTB/RIF results was 1.0% (95% CrI 0.4 to 2.0) (Kohli 2018).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Kohli 2018
The cited source says what the claim attributes to it.
In the citing paper
“We previously reported that for pleural fluid, of 1416 tests performed the pooled proportion of inconclusive Xpert MTB/RIF results was 1.2% (95% CrI 0.4 to 2.6) (Kohli 2018).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Kohli 2018
The cited source says what the claim attributes to it.
In the citing paper
“We previously reported that for rifampicin resistance testing, of 1003 tests performed, the pooled proportion of indeterminate Xpert MTB/RIF results was 2.6% (95% CrI 1.4 to 4.3) (Kohli 2018).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Kohli 2018
The cited source says what the claim attributes to it.
In the citing paper
“For Xpert MTB/RIF, we previously reported that in 10 studies involving 6975 specimens with 141 NTMs, Xpert MTB/RIF was negative in all specimens (Kohli 2018).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Kohli 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility
Lunn, D. J., Thomas, A., Best, N., & Spiegelhalter, D. J. (2000) · Statistics and Computing · doi:10.1023/a:1008929526011 · Cited by 5,397
STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2015) · BMJ · doi:10.1136/bmj.h5527 · Cited by 3,660
Reitsma, J. B., Glas, A. S., Rutjes, A. W. S., Scholten, R. J. P. M., Bossuyt, P. M., & Zwinderman, A. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.02.022 · Cited by 3,369
The BUGS project: evolution, critique and future directions
Lunn, D., Spiegelhalter, D., Thomas, A., & Best, N. (2009) · Statistics in Medicine · doi:10.1002/sim.3680 · Cited by 1,876
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brożek, J., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw376 · Cited by 1,537
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.16141 · Cited by 1,524
Flagged first, then by citations
5 of the 218 references couldn’t be matched to a known paper.
Research works printed but not linked: 13
- Jing, 2017, Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China, International Journal of Clinical and Experimental Pathology, 10, 4847
- Peñata, 2016, Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method, Biomedica, 36 Suppl 1, 78
- Bemba, 2017, Performance of GeneXpert MTB / RIF in the diagnosis of pleural tuberculosis in Brazzaville: a preliminary report, Health Sciences and Diseases, 18, 21
- Gascoyne-Binzi, 2012, Comparison of on-demand PCR testing for Mycobacterium tuberculosis with culture and batched PCR, Clinical Microbiology and Infection, 18, 543
- Ioannidis, 2010, Tuberculosis resistance detection rate to the two main anti-TB drugs, isoniazid and rifampicin, using molecular techniques: experience of the Hellenic National Reference Center for Mycobacteria. [Greek], Acta Microbiologica Hellenica, 55, 175
- Mishra, 2017, Study of diagnostic utility of Xpert MTB/RIF test on pleural fluid in the evaluation of patients presenting with pleural tuberculosis in high prevalence setting, American Journal of Respiratory and Critical Care Medicine, 195, A2088
- Veritas Health Innovation Covidence systematic review software. Available at www.covidence.org 2017
- Gupta-Wright A Corbett EL van Oosterhout JJ Wilson DK Grint D Alufandika-Moyo M Urine-based screening for tuberculosis: a randomized trial in HIV-positive inpatients (the STAMP trial) Conference on retroviruses and opportunistic infections (CROI). www.croiconference.org/sessions/urine-based-screening-tuberculosis-randomized-trial-hiv-positive-inpatients Boston 2018 38LB
- Macaskill P Gatsonis C Deeks JJ Harbord RM Takwoingi Y Chapter 10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, C Gatsonis (editors). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010 http://srdta.cochrane.org/
- Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014
- Schünemann HJ Oxman AD Gunn EV Higgins JPT Deeks JL Glasziou P Chapter 11. Presenting results and "Summary of findings" tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
- Boyle, 2017, Tuberculosis Diagnostics Technology and Market Landscape
- World Health Organization, 2017, Global tuberculosis report
Cited by
Sorted by citations
Items 201–244 of 244
Tuberculous and Septic Arthritis
Handa, R. (2021) · Springer eBooks · doi:10.1007/978-981-33-4885-1_27 · Cited by 1
Facteurs prédictifs et biomarqueurs de la pleurésie exsudative lymphocytaire tuberculeuse
Kouméka, P. P., Ouldittou, I., Fikri, O., Saidi, I., Batahar, S. A., & Àmro, L. (2021) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2020.11.001 · Cited by 1
Pulmonary, Pleural and Mediastinal TB: Clinical Aspects and Diagnosis
Park, M., Ross, C., & Kon, O. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-75509-6_3 · Cited by 1
Golden, L. A., Chaya, S., Reichmuth, K., Visagie, A., Ayuk, A. C., Owusu, S. K., Marangu, D., Affendi, N., Lakhan, A., Gray, D. M., et al. (2021) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/ajtccm.2021.v27i4.152 · Cited by 1
Mba, B., Lucas, B., Houchens, N., Seares, J. M., & Joshi, U. (2019) · Journal of Hospital Medicine · doi:10.12788/jhm.3286 · Cited by 1
Schloßhauer, T., Priepke, E., Rehart, S., Kuehn, S., Jahn-Muehl, B., & Rieger, U. M. (2019) · Handchirurgie · Mikrochirurgie · Plastische Chirurgie · doi:10.1055/a-0840-3513
Facteurs prédictifs et biomarqueurs de la pleurésie exsudative lymphocytaire tuberculeuse
Kouméka, P. P., Batahar, S. A., & Àmro, L. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/j.rmra.2019.11.620
The authors respond: Diagnosis of Extrapulmonary Tuberculosis and Avoiding Anchoring Bias
Long, B., Liang, S. Y., Koyfman, A., & Gottlieb, M. A. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.01.030
Laboratory methods for detecting tuberculosis and tuberculous meningitis
Chin, J. H., & Ssengooba, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818825-5.00004-8
FluoroType® MTB in pleural fluid for diagnosing tuberculosis
Bielsa, S., Bernet, A., Civit, C., Acosta, C., Manonelles, A., & Porcel, J. M. (2021) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2020.04.010
Xpert MTB/RIF on pleural biopsy in suspected pleural TB: Does it add anything other than cost?
Koegelenberg, C., & Shaw, J. A. (2021) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/ajtccm.2021.v27i1.136
Tuberculous parotitis in an immuno-competent adult: A rare clinical entity
Jibril, Y. N., Bello‐Muhammad, N., Adamu, A., & Ajiya, A. (2021) · Pyramid Journal of Medicine · doi:10.4081/pjm.2020.108
Dietz, J. D. C., Borges, M. S., Alves, S. L. D. Á., Dias, D. X. R., & Manrique, E. J. C. (2021) · Research Society and Development · doi:10.33448/rsd-v10i7.16533
Molecular Methods and Culture in Diagnosis of Tuberculous Meningitis in Children
Sharma, G., Malhotra, B., John, P., & Bhargava, S. (2021) · Journal of Microbiology and Infectious Diseases · doi:10.5799/jmid.993883
The perplexing pleura: Diagnosing tuberculosis pleural eusions in the era of drug resistance
Shaw, J. A., & Irusen, E. M. (2019) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/sarj.2019.v25i2.020
He, X., Zhang, Y., Zhou, Y. Y., Li, L., & Li, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-2175393/v1
Swanson, D. S., & Harrison, C. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-75608-2.00041-0
Research Progress in Laboratory Examination of Tuberculous Pleurisy
陈, 波. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1351031
Almagambetova, A., Yermekbayeva, K. Z., Dilmagambetov, D. S., Tanzharykova, G. N., & Baisalbayev, B. S. (2023) · Infezioni in Medicina · doi:10.53854/liim-3102-11
Chapitre 7: La tuberculose extrapulmonaire
Barss, L., Connors, W. J. A., & Fisher, D. (2023) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2023.2226005
Nicolás Utrera, Q., Benjamín Zúñiga, P., Pilar Gajardo, O., Natalia Tamblay, N., & Nicolás Pons, C. (2023) · Revista de otorrinolaringología y cirugía de cabeza y cuello · doi:10.4067/s0718-48162023000400402
Liu, L.-B., Wang, C.-Y., Mei, B., Wang, J., Xu, X., Zhou, H.-J., & Cai, L. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s473027
Líquido sinovial normal y patológico
Bardin, T., Damiano, J., & Ea, H. (2024) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(24)49406-9
Molecular diagnosis of an unusual aetiology of chronic abdominal pain with ascites
Mohamed, A., Lin, K. Y., Karabakhtsian, R. G., Chacko, K. R., Bartash, R. M., Liu, Q., & Meyerowitz, E. A. (2024) · BMJ Case Reports · doi:10.1136/bcr-2024-261110
Enfoque diagnóstico en el paciente con derrame pleural
W, M. O. (2024) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2024.05.010
Primary Infection by Pericardial Tuberculosis in Immunocompetent Patient
Rene, N. S. E., Sergio, A. F., Yair, R. G. J., & Melchor, A. B. (2024) · Scholars Journal of Medical Case Reports · doi:10.36347/sjmcr.2024.v12i12.020
Mohsin, R., Ali, M., Siddique, M., Zaheer, M., Ambreen, A., & Khanum, H. (2024) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v5i10.1818
HIV complicated with severe pulmonary adenocarcinoma: A case report
Zhang, T., Wang, H., Han, W., Qian, X., Li, Q., Ren, T., & Wang, M. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12816
Laboratory diagnosis of pleural tuberculosis: An unsolved enigma
Mohapatra, A., Gaikwad, U., Ganga, R. T., & Sharma, P. S. (2025) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2025.100817
Toshniwal, A., Chaudhary, S., Hanumanthaiah, V., Ghewade, B., & Jain, A. (2025) · IDCases · doi:10.1016/j.idcr.2025.e02257
Pallathadka, H., Mishra, D. K., Roy, P. D., Deka, B. C., Saha, J., Kataky, S. S., & Lahkar, M. (2025) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.4.3.1
Araz, H., Kazcı, S., Eser, F., & Aypak, A. (2025) · Ankara Üniversitesi Tıp Fakültesi Mecmuası · doi:10.65092/autfm.1722836
Maafi, K., Nafi, I., Laariche, F., Nabil, M., Abidar, H., Souly, K., & Aboudkhil, S. (2026) · Natural Built Social Environment Health · doi:10.63095/nbseh.26.455534
Hu, Y., Liu, P., Mei, M., Quan, C., & Liu, Q. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1736555
Nisha, N., Sharma, J. B., Deoghare, M., Aggarwal, A., Khan, M., & Kumari, R. (2026) · International Urogynecology Journal · doi:10.1007/s00192-026-06674-9
Analytical Review of Diagnostic Methods of Female Genital and Peritoneal Tuberculosis
Соцкий, П. О., Sotskaya, O. L., & Safarian, M. D. (2026) · Tuberculosis and lung diseases · doi:10.58838/2075-1230-2026-104-2-110-120
Optimizing the Diagnosis of Tuberculous Pericarditis through the Use of GeneXpert MTB/RIF
Maafi, K., Abidar, H., Souly, K., & Aboudkhil, S. (2026) · Natural Built Social Environment Health · doi:10.63095/nbseh.26.695425
Zhang, G., Li, T., Chen, J. W., Hu, X., Li, S., Li, Y., Tang, M., Liu, S., Guo, C., & Gao, Q. (2026) · Research Square · doi:10.21203/rs.3.rs-9186384/v1
Cagua-Ordoñez, J. C., Parise-Vasco, J. M., Angamarca-Iguago, J., Fuentes-Tumbaco, N. B., & Simancas‐Racines, D. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1892055 · Cited by 1
Gupta, A. K., Basak, P., & Mishra, R. (2026) · PAIN JOINTS SPINE · doi:10.1922/pjs.16.7s.2026.1056
Guo, Y., Liu, X., Yang, C., Gu, S., Gao, W., & Zeng, Y. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1779279
Pathogen and host biomarkers to aid early diagnosis and prognosis of tuberculous meningitis
Singh, U. B., Angitha, K. P., Adarsh, A. K., Bala, K., Wig, N., Srivastava, A. K., & Kanga, U. (2026) · Infection · doi:10.1007/s15010-026-02941-5
Guled, A. M., Nuh, A. M., Mohamed, M. A., Muse, A. H., Ali, H. A., Abdi, H. A., Abdiqadir, M. A., yonis, A. Y., & Salih, O. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1982502
Metadata
- Authors
- Kohli, M., Schiller, I., Dendukuri, N., Dheda, K., Denkinger, C. M., Schumacher, S. G., & Steingart, K. R.
- Affiliations
- McGill University (CA)
- McGill University Health Centre (CA)
- University of Cape Town (ZA)
- FIND (CH)
- Liverpool School of Tropical Medicine (GB)
- Corresponding author
- Steingart, Karen R
- ORCID
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2018-08-27
- Volume
- 8
- Pages
- CD012768-CD012768
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC6513199
- OpenAlex
- W2748797449
- Cited by
- 245
- References
- 218
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 34 · 2023: 28 · 2022: 33 · 2021: 44 · 2020: 45 · 2019: 34 · 2018: 1
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Update notices
- new_version (2021-01-15)
- Open access
- bronze
- doi.org
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Funders
- Beijing University of Chinese Medicine
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Infectious Diseases › Diagnosis and treatment of tuberculosis
- Keywords
- Xpert MTB/RIF, extrapulmonary tuberculosis, rifampicin resistance, Mycobacterium tuberculosis complex, diagnostic accuracy, tuberculous meningitis, pleural tuberculosis, tuberculous lymphadenitis, osteoarticular tuberculosis, urogenital tuberculosis, tuberculous pericarditis, tuberculous peritonitis, nucleic acid amplification tests, latent class analysis, sensitivity and specificity
- MeSH terms
- Antibiotics, Antitubercular, Bacterial Proteins, False Negative Reactions, False Positive Reactions, Humans, Mycobacterium tuberculosis, Reagent Kits, Diagnostic, Reference Standards, Rifampin, DNA-Directed RNA Polymerases, Sensitivity and Specificity, Tuberculosis, Tuberculosis, Meningeal, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
